Physiological Dead Space and Intensive Care Mortality in Mechanically Ventilated Patients (NCT06963944) | Clinical Trial Compass
CompletedNot Applicable
Physiological Dead Space and Intensive Care Mortality in Mechanically Ventilated Patients
Turkey (Türkiye)60 participantsStarted 2024-01-01
Plain-language summary
This study investigates the relationship between physiological dead space and clinical outcomes, specifically mortality and discharge status, in adult patients receiving invasive mechanical ventilation in the intensive care unit (ICU). Physiological dead space refers to ventilated but non-perfused regions of the lungs and can be quantified using the Enghoff-modified Bohr equation based on capnographic and arterial CO₂ measurements.
While volumetric capnography is a valuable tool in anesthesiology and perioperative care, its use in ICU settings remains limited. By continuously monitoring physiological dead space at the bedside, this study aims to provide real-time insight into ventilation-perfusion mismatch and assess its prognostic significance in critically ill patients.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Admitted to the intensive care unit
* Receiving invasive mechanical ventilation
* Monitored with volumetric capnography and arterial blood gas analysis
* Informed consent obtained from legal representatives
Exclusion Criteria:
* Patients under 18 years of age
* ICU length of stay less than 24 hours
* Patient or legal representative refused participation
* Hemoglobin level \< 7 g/dL
* Arterial PaCO₂ \> 70 mmHg
* Signs of circulatory failure
* Lactate \> 4 mmol/L
* Capillary refill time \> 3 seconds
* PaCO₂ - Central venous CO₂ gradient \> 8 mmHg (if applicable)
* Mean arterial pressure (MAP) \< 65 mmHg
* Mottling score ≥ 2
* Body temperature \> 38°C
* Arterial pH \< 7.20
* Body mass index (BMI) \> 40 kg/m²
* Carbon dioxide production (VCO₂) \> 4 mL/kg
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.